Log in

BIOLASE Stock Price, News & Analysis (NASDAQ:BIOL)

$0.81
-0.04 (-4.69 %)
(As of 10/17/2019 07:42 AM ET)
Today's Range
$0.80
Now: $0.81
$0.90
50-Day Range
$0.75
MA: $0.95
$1.09
52-Week Range
$0.75
Now: $0.81
$2.87
Volume68,074 shs
Average Volume75,611 shs
Market Capitalization$17.85 million
P/E RatioN/A
Dividend YieldN/A
Beta2.25
BIOLASE, Inc, a medical device company, develops, manufactures, markets, and sells laser systems in dentistry and medicine for patients and health care professionals in the worldwide. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; and diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Read More…

Industry, Sector and Symbol

Industry Dental equipment & supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BIOL
Previous SymbolNASDAQ:BLTI
CUSIPN/A
Phone949-361-1200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$46.15 million
Book Value$0.54 per share

Profitability

Net Income$-21,520,000.00

Miscellaneous

Employees190
Market Cap$17.85 million
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable

Receive BIOL News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOL and its competitors with MarketBeat's FREE daily newsletter.


BIOLASE (NASDAQ:BIOL) Frequently Asked Questions

What is BIOLASE's stock symbol?

BIOLASE trades on the NASDAQ under the ticker symbol "BIOL."

When did BIOLASE's stock split? How did BIOLASE's stock split work?

BIOLASE's stock reverse split on Friday, May 11th 2018. The 1-5 reverse split was announced on Thursday, May 10th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 10th 2018. An investor that had 100 shares of BIOLASE stock prior to the reverse split would have 20 shares after the split.

How were BIOLASE's earnings last quarter?

BIOLASE Inc (NASDAQ:BIOL) released its quarterly earnings data on Thursday, August, 8th. The medical technology company reported ($0.15) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.18) by $0.03. The medical technology company earned $8.65 million during the quarter, compared to the consensus estimate of $12.76 million. BIOLASE had a negative return on equity of 159.26% and a negative net margin of 47.46%. View BIOLASE's Earnings History.

When is BIOLASE's next earnings date?

BIOLASE is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for BIOLASE.

What price target have analysts set for BIOL?

4 equities research analysts have issued 12-month price targets for BIOLASE's shares. Their forecasts range from $2.00 to $3.00. On average, they anticipate BIOLASE's share price to reach $2.50 in the next twelve months. This suggests a possible upside of 207.5% from the stock's current price. View Analyst Price Targets for BIOLASE.

What is the consensus analysts' recommendation for BIOLASE?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIOLASE in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BIOLASE.

Has BIOLASE been receiving favorable news coverage?

News headlines about BIOL stock have been trending very negative on Thursday, InfoTrie Sentiment reports. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. BIOLASE earned a media sentiment score of -3.2 on InfoTrie's scale. They also assigned news headlines about the medical technology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for BIOLASE.

Are investors shorting BIOLASE?

BIOLASE saw a increase in short interest during the month of September. As of September 15th, there was short interest totalling 585,000 shares, an increase of 11.4% from the August 15th total of 525,000 shares. Based on an average trading volume of 49,600 shares, the short-interest ratio is currently 11.8 days. Currently, 2.7% of the company's shares are short sold. View BIOLASE's Current Options Chain.

Who are some of BIOLASE's key competitors?

What other stocks do shareholders of BIOLASE own?

Who are BIOLASE's key executives?

BIOLASE's management team includes the folowing people:
  • Mr. Todd A. Norbe, Pres, CEO & Director (Age 52)
  • Mr. John R. Beaver, Exec. VP & CFO (Age 58)
  • Mr. Richard R. Whipp, VP of Operations (Age 67)
  • Mr. William E. Brown Jr., VP of Bus. Devel. (Age 71)
  • Mr. Daniel Merkin, National Sales Director (Age 46)

How do I buy shares of BIOLASE?

Shares of BIOL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is BIOLASE's stock price today?

One share of BIOL stock can currently be purchased for approximately $0.81.

How big of a company is BIOLASE?

BIOLASE has a market capitalization of $17.85 million and generates $46.15 million in revenue each year. The medical technology company earns $-21,520,000.00 in net income (profit) each year or ($0.85) on an earnings per share basis. BIOLASE employs 190 workers across the globe.View Additional Information About BIOLASE.

What is BIOLASE's official website?

The official website for BIOLASE is http://www.biolase.com/.

How can I contact BIOLASE?

BIOLASE's mailing address is 4 Cromwell, Irvine CA, 92618. The medical technology company can be reached via phone at 949-361-1200 or via email at [email protected]


MarketBeat Community Rating for BIOLASE (NASDAQ BIOL)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  238 (Vote Outperform)
Underperform Votes:  230 (Vote Underperform)
Total Votes:  468
MarketBeat's community ratings are surveys of what our community members think about BIOLASE and other stocks. Vote "Outperform" if you believe BIOL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/17/2019 by MarketBeat.com Staff

Featured Article: Bond

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel